ReviewBundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz2026
[Use of vaccines to prevent the development of bacterial resistance].
Review in Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccinations against bacterial pathogens play a crucial role in infection prevention, especially given the growing prevalence of antibiotic resistance. Historically, vaccines against cholera, diphtheria, and pertussis (whooping cough) marked the first significant advances in the fight against bacterial diseases. Later, vaccines against meningococcus and tetanus, among others, were added. These active immunizations expose the immune system to components of the pathogen, stimulating the production of antibodies, T helper cells, B cells, and memory cells, thereby providing long-term protection. The targeted development of new vaccines, even against difficult-to-treat bacterial pathogens, is enabled by a wide range of vaccine types, including inactivated, toxoid-based, and recombinant vaccines, as well as modern approaches such as reverse vaccinology and messenger Ribonucleic Acid (mRNA) technologies combined with enhancing adjuvants. In addition to active immunization, passive immunization, in which pathogen-specific antibodies are administered directly, also plays an important role.At the population level, clear epidemiological effects of vaccination programs are evident, as vaccinations protect not only individuals but also communities, thus contributing to public health. Despite the clear medical and economic advantages of vaccination programs, their acceptance among the population must be significantly increased through objective information policies. Currently, numerous vaccines are under development, which, through innovative technologies, are opening up new avenues for effectively preventing and controlling bacterial infections-a crucial step in an era of increasing antibiotic resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.